Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVO
Alvotech
$9.38
+18.1%
$9.47
$7.35
$14.65
$2.83B-0.02131,302 shs1.03 million shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$14.30
+3.0%
$16.57
$12.72
$34.47
$2.43B0.751.21 million shs940,588 shs
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$22.25
+14.7%
$20.03
$16.06
$26.55
$901.19M0.62193,078 shs670,125 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$27.85
+1.1%
$26.20
$18.92
$81.81
$3.13B0.754.11 million shs3.59 million shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVO
Alvotech
+17.85%+18.14%+16.38%-27.34%-30.72%
Immunovant, Inc. stock logo
IMVT
Immunovant
+3.03%-10.06%+7.44%-29.94%-51.95%
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
+14.75%+19.62%+24.44%-6.08%+29.51%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
+1.00%-2.66%+39.39%-14.47%-65.15%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alvotech stock logo
ALVO
Alvotech
1.8013 of 5 stars
3.52.00.00.02.60.00.6
Immunovant, Inc. stock logo
IMVT
Immunovant
2.1517 of 5 stars
4.50.00.00.02.61.70.0
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
3.4397 of 5 stars
0.83.01.71.13.43.32.5
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.6186 of 5 stars
4.52.00.04.73.53.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alvotech stock logo
ALVO
Alvotech
3.00
Buy$18.0091.90% Upside
Immunovant, Inc. stock logo
IMVT
Immunovant
2.90
Moderate Buy$38.33168.07% Upside
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
1.50
Reduce$20.00-10.11% Downside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
3.00
Buy$87.15212.94% Upside

Current Analyst Ratings Breakdown

Latest PAHC, ALVO, IMVT, and VKTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$20.00 ➝ $21.00
4/29/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/28/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$104.00
4/28/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$95.00 ➝ $75.00
4/24/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$105.00 ➝ $102.00
4/24/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$102.00 ➝ $102.00
4/22/2025
Immunovant, Inc. stock logo
IMVT
Immunovant
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$38.00 ➝ $17.00
4/17/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$102.00 ➝ $102.00
4/15/2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$20.00
4/8/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$30.00
3/26/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$102.00 ➝ $102.00
(Data available from 5/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alvotech stock logo
ALVO
Alvotech
$489.68M5.77N/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/A$2.08 per shareN/A
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$1.11B0.81$2.05 per share10.87$6.09 per share3.65
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$3.48 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alvotech stock logo
ALVO
Alvotech
-$551.73M-$0.87N/A46.90N/A-123.47%N/A-35.87%5/20/2025 (Estimated)
Immunovant, Inc. stock logo
IMVT
Immunovant
-$259.34M-$2.62N/AN/AN/AN/A-77.94%-69.82%6/4/2025 (Estimated)
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$2.42M$0.4846.3510.600.451.75%25.35%6.21%N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$109.96M-$1.15N/AN/AN/AN/A-11.93%-11.57%7/23/2025 (Estimated)

Latest PAHC, ALVO, IMVT, and VKTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/4/2025Q4 2025
Immunovant, Inc. stock logo
IMVT
Immunovant
-$0.72N/AN/AN/AN/AN/A
5/20/2025Q1 2025
Alvotech stock logo
ALVO
Alvotech
-$0.17N/AN/AN/A$95.02 millionN/A
5/7/2025Q1 2025
Alvotech stock logo
ALVO
Alvotech
-$0.17$0.35+$0.52$0.35N/AN/A
5/7/2025Q3 2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$0.52$0.63+$0.11$0.51$352.41 million$347.80 million
4/23/2025Q1 2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.31-$0.41-$0.10-$0.41N/AN/A
3/26/2025Q4 2024
Alvotech stock logo
ALVO
Alvotech
-$0.74-$0.24+$0.50-$0.24$97.99 million$153.34 million
2/10/2025Q3 2025
Immunovant, Inc. stock logo
IMVT
Immunovant
-$0.68-$0.76-$0.08-$0.76N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alvotech stock logo
ALVO
Alvotech
N/AN/AN/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/AN/A
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$0.482.16%N/A100.00%N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A

Latest PAHC, ALVO, IMVT, and VKTX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/6/2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
quarterly$0.122.52%6/4/20256/4/20256/25/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alvotech stock logo
ALVO
Alvotech
N/A
2.69
1.92
Immunovant, Inc. stock logo
IMVT
Immunovant
N/A
6.04
6.04
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
2.99
3.20
1.37
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
36.47
36.47

Institutional Ownership

CompanyInstitutional Ownership
Alvotech stock logo
ALVO
Alvotech
N/A
Immunovant, Inc. stock logo
IMVT
Immunovant
47.08%
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
99.34%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%

Insider Ownership

CompanyInsider Ownership
Alvotech stock logo
ALVO
Alvotech
0.46%
Immunovant, Inc. stock logo
IMVT
Immunovant
5.90%
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
50.07%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alvotech stock logo
ALVO
Alvotech
4301.48 millionN/ANot Optionable
Immunovant, Inc. stock logo
IMVT
Immunovant
120169.86 million159.84 millionOptionable
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
1,86040.50 million20.22 millionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
20112.31 million106.20 millionOptionable

Recent News About These Companies

Brokers Offer Predictions for VKTX FY2025 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alvotech stock logo

Alvotech NASDAQ:ALVO

$9.38 +1.44 (+18.14%)
Closing price 05/8/2025 04:00 PM Eastern
Extended Trading
$9.54 +0.16 (+1.71%)
As of 05/8/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Immunovant stock logo

Immunovant NASDAQ:IMVT

$14.30 +0.42 (+3.03%)
Closing price 05/8/2025 04:00 PM Eastern
Extended Trading
$14.30 0.00 (0.00%)
As of 05/8/2025 06:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$22.25 +2.86 (+14.75%)
Closing price 05/8/2025 04:00 PM Eastern
Extended Trading
$22.25 0.00 (0.00%)
As of 05/8/2025 07:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$27.85 +0.29 (+1.05%)
Closing price 05/8/2025 04:00 PM Eastern
Extended Trading
$27.58 -0.27 (-0.95%)
As of 05/8/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.